OTC Watch

All stocks / EVFM

Evofem Biosciences, Inc. EVFM

Evofem Biosciences (EVFM): convertible notes mentioned in an 8-K in October 2026 and the latest annual figures in plain language. Each fact links to its SEC filing.

Estimated floatCostly financing OTCIDCalifornia, USA
Live quote on OTC Markets

Market listing

Full name
EVOFEM BIOSCIENCES INC
Market tier
OTC Pink Current
Trading status
Active
Last trade
Nov 16
Website
www.evofem.com/
Source: Stockwatch, 2026-11-17

News headlines

Evofem Biosciences Adds Additional Manufacturing Capacity for PHEXX(TM) to Support Global Growth Strategy
2026-09-23 16:05 · News Release
Evofem Biosciences Celebrates Shipment of Its 500,000th Unit of PHEXX(TM), Representing Hormone-Free Protection from Unintended Pregnancy for 6 Million Acts of Sex
2026-07-23 08:55 · News Release
HUB Cyber Security Expands Into Women's Health With Zero-Cash Acquisition of Evofem Notes, Advances Balance Sheet Turnaround
2026-07-01 07:00 · News Release
Evofem Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-18 08:55 · News Release
Evofem Announces Exclusive Agreement for the Distribution and Commercialization of SOLOSEC in Sub-Saharan Africa
2026-04-27 09:25 · News Release
Evofem Reports Fifth Consecutive Year of Net Sales Growth
2026-03-11 16:05 · News Release
Evofem CEO Saundra Pelletier Calls for a "Ground-Up Reset" of Women's Health at Fierce JPM Week 2026
2026-01-23 09:25 · News Release
Evofem Expands "Say Vagina" Campaign With Launch of Say Vagina Store
2026-01-21 11:00 · News Release
Favorable Pricing Certificates Issued for Evofem's PHEXX by Emirates Drug Establishment are Launching Step for Commercialization in UAE
2025-11-21 09:25 · News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2025-12-31
The report says
Revenue
$20,183,000
Net income
$391,000
What it means

It earned more than it spent

Steady

After all costs, the company kept $391,000 as profit in the year.

The report says
Cash and cash equivalents
$578,000
Net cash used in operating activities
($1,992,000)
What it means

The cash could run out soon

Under strain

It had $578,000 in the bank and used about $166,000 a month. At that pace the money lasts about 3 months unless it borrows or sells more shares.

The report says
Total assets
$20,274,000
Total liabilities
$89,711,000
What it means

It owes more than it owns

Under strain

Everything the company owns adds up to $20.3 million. Its debts and unpaid bills add up to $89.7 million. That is about $4.42 owed for every $1 owned.

What this adds up to

2 of 3 checks show strain. The cash could run out soon. It owes more than it owns. These are facts from the company's own reports, not a recommendation.

Signals

Estimated float2026-11-09

Estimated float about 132,530,081 shares as of 2026-11-09: 132,530,081 outstanding minus 0 held by 0 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Costly financing2026-10-15

8-K filed 2026-10-15 mentions: convertible note.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Costly financing2026-04-16

8-K filed 2026-04-16 mentions: convertible note.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Shares outstanding

Source: SEC filings
2025-12-31
126.7M
2026-03-09
132.5M
2026-03-31
132.5M
2026-05-11
132.5M
2026-06-30
132.5M
2026-08-12
132.5M
2026-09-30
132.5M
2026-11-09
132.5M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-11-13 10-Q10-Q
2026-11-13 8-K8-K
2026-10-15 8-K8-K
2026-09-23 8-K8-K
2026-08-14 10-Q10-Q
2026-08-04 SCHEDULE 13D
2026-07-20 8-K8-K
2026-07-14 8-K8-K
2026-05-18 8-K8-K
2026-05-15 10-Q10-Q
2026-04-30 8-K8-K
2026-04-16 8-K8-K

Common questions about EVFM

Does EVFM file reports with the SEC?

Yes. Evofem Biosciences files with the SEC under company number 0001618835. The most recent filing we hold is a 10-Q dated 2026-11-13.

Source record

How many EVFM shares are outstanding?

132,530,081 shares as of 2026-11-09, as reported to the SEC.

Source record

Has EVFM filed reports late?

We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.

Is Evofem Biosciences making money?

After all costs, the company kept $391,000 as profit in the year. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)

Source record